These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52. Treatment with linezolid and rifampicin for 18 months for recurrent infection of a megaprosthesis in a patient with Ewing's sarcoma. Prugger V; Egner S; Windhager R; Mitteregger M; Bertha G; Wenisch C Int J Antimicrob Agents; 2004 Dec; 24(6):628-30. PubMed ID: 15555895 [No Abstract] [Full Text] [Related]
53. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Villar M; Sotgiu G; D'Ambrosio L; Raymundo E; Fernandes L; Barbedo J; Diogo N; Lange C; Centis R; Migliori GB Eur Respir J; 2011 Sep; 38(3):730-3. PubMed ID: 21885418 [No Abstract] [Full Text] [Related]
54. [Linezolid and tuberculosis, a new and useful treatment]. Sequi Canet JM; Bernal Ferrer A; Sala Langa MJ An Pediatr (Barc); 2008 Mar; 68(3):306-7. PubMed ID: 18358149 [No Abstract] [Full Text] [Related]
55. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis. Yew WW; Chau CH; Wen KH Int J Tuberc Lung Dis; 2008 Mar; 12(3):345-6. PubMed ID: 18284844 [No Abstract] [Full Text] [Related]
56. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Sun F; Ruan Q; Wang J; Chen S; Jin J; Shao L; Zhang Y; Zhang W Antimicrob Agents Chemother; 2014 Oct; 58(10):6297-301. PubMed ID: 25092692 [TBL] [Abstract][Full Text] [Related]
57. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Sotgiu G; Lange C; Richardson MD; Matteelli A; Centis R; Eker B; Guenther G; Spanevello A; Migliori GB; J Antimicrob Chemother; 2009 Oct; 64(4):879-83; author reply 883-4. PubMed ID: 19651787 [No Abstract] [Full Text] [Related]